Screening Strategies Among High-risk Populations for Anal Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-80
SponsorLisa Flowers
About this trial
The goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (aHSIL), a precancerous condition of anal cancer, among populations at high risk for anal cancer and 2) characterize DNA methylation, immunologic response, and environmental factors associated with aHSIL.
Eligibility criteria
Qualifiers
30-80 years of age
Individuals with chronic impaired immune status
History of high-grade lower genital tract neoplasia (LGTN), Zubrod Performance Status of 0-2;
Disqualifiers
Patients treated for aHSIL less than 6 months before screening,
History of anal cancer and pregnant women.
Trial design
Treatments tested in this trial
- HRA + Biopsy
- Anal Cytology
- Genotyping of anal hrHPV infection
- CINtec®PLUS
Treatment groups
500 Participants
are divided into 4 treatment groupsSponsors and collaborators
Lisa Flowers
Lead sponsor
Emory University
Sponsor institution
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov